Abstract
The regulation of the immune system at the cell surface is primarily controlled by two families of cosignaling molecules: the immunoglobulin (Ig) superfamily, or CD28 and B7 family, and the tumor necrosis factor receptor (TNFR) family. Here, we summarized the principal structural and functional characteristics of both families. In this respect, the interaction between HVEM, a TNF receptor, and BTLA, an Ig family member, has provided a new perspective and an additional level of complexity in the crosstalk between these two regulatory systems. This review will present a summary of the recent advances in the immunobiology of the LIGHT-HVEM-LTβR-BTLA network. The LIGHT-HVEM-BTLA system has emerged as a major regulator of immune responses and lymphocyte activation, whereas LIGHT-LTβR participates in lymphoid tissue development and cell death. Moreover, recent studies have provided encouraging new insights into the roles of the LIGHT-HVEM-LTβR-BTLA axis as a potential target for controlling anti-tumor responses.
Current Molecular Medicine
Title: Cosignaling Molecules Around LIGHT-HVEM-BTLA: From Immune Activation to Therapeutic Targeting
Volume: 9 Issue: 7
Author(s): Christine Pasero, Alemseged Truneh and Daniel Olive
Affiliation:
Abstract: The regulation of the immune system at the cell surface is primarily controlled by two families of cosignaling molecules: the immunoglobulin (Ig) superfamily, or CD28 and B7 family, and the tumor necrosis factor receptor (TNFR) family. Here, we summarized the principal structural and functional characteristics of both families. In this respect, the interaction between HVEM, a TNF receptor, and BTLA, an Ig family member, has provided a new perspective and an additional level of complexity in the crosstalk between these two regulatory systems. This review will present a summary of the recent advances in the immunobiology of the LIGHT-HVEM-LTβR-BTLA network. The LIGHT-HVEM-BTLA system has emerged as a major regulator of immune responses and lymphocyte activation, whereas LIGHT-LTβR participates in lymphoid tissue development and cell death. Moreover, recent studies have provided encouraging new insights into the roles of the LIGHT-HVEM-LTβR-BTLA axis as a potential target for controlling anti-tumor responses.
Export Options
About this article
Cite this article as:
Pasero Christine, Truneh Alemseged and Olive Daniel, Cosignaling Molecules Around LIGHT-HVEM-BTLA: From Immune Activation to Therapeutic Targeting, Current Molecular Medicine 2009; 9 (7) . https://dx.doi.org/10.2174/156652409789105589
DOI https://dx.doi.org/10.2174/156652409789105589 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Obstructive Sleep Apnea and Atrial Arrhythmogenesis
Current Cardiology Reviews LCHAD and MTP Deficiencies - Two Disorders of Mitochondrial Fatty Acid β-Oxidation with Unusual Features
Current Pediatric Reviews RNAi-based Gene Therapy for Dominant Limb Girdle Muscular Dystrophies
Current Gene Therapy Patent Selections
Recent Patents on Cardiovascular Drug Discovery Do Advanced Glycation End Products (AGEs) Contribute to the Comorbidities of Polycystic Ovary Syndrome (PCOS)?
Current Pharmaceutical Design Editorial [Hot topic: Innate Immunity Molecules S100A8/A9 Involved in Stress Response and Cancer Biology (Guest Editors: Claus Kerkhoff and Saeid Ghavami)]
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Role of Heme Oxygenase-1 in Cardiovascular Function
Current Pharmaceutical Design Meet Our Editorial Board Member
Current Cardiology Reviews Perioperative Considerations in Diabetic Patients
Current Diabetes Reviews Proteomics and Cardiovascular Disease: An Update
Current Medicinal Chemistry Normal Ventricular Functional Reference Parameters on Magnetic Resonance Imaging in Healthy Children
Current Medical Imaging AMI and Anabolic-Androgenic Steroids: Case Report with Systematic Review
Current Cardiology Reviews Peripheral Heart Blocks Associated with Myocardial Infarcts: Clinical Diagnosis Based on Experimental Findings
Current Cardiology Reviews Protein Phosphatase Inhibition: Structure Based Design. Towards New Therapeutic Agents
Current Pharmaceutical Design Prospectives of Antihypertensive Nano-ceuticals as Alternative Therapeutics
Current Drug Targets Vitamins in Heart Failure: Friend or Enemy?
Current Pharmaceutical Design Macrovascular Complications of Type 2 Diabetes Mellitus
Current Vascular Pharmacology New Therapeutic Aspects of Inflammatory Cardiomyopathy
Current Pharmaceutical Design New Approach to Immunotherapy Against Organ-specific Autoimmune Diseases with T Cell Receptor and Chemokine Receptor DNA Vaccines
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Nitric Oxide-Derived Oxidants with a Focus on Peroxynitrite: Molecular Targets,Cellular Responses and Therapeutic Implications
Current Pharmaceutical Design